P165 Association between vitamin D deficiency and extended duration of COVID-19 symptoms

SA Roberts, ST Lugg, AA Faniyi, SE Faustini, C Faniyi, J Duffy, M Hewison, A Shields, AG Richter, D Parekh, A Scott, DR Thickett

Research output: Contribution to journalAbstractpeer-review

Abstract

Introduction and Objectives Vitamin D (VD) is involved in immunity and inflammation through mechanisms such as renin inhibition and inflammatory cytokine reduction. There is already evidence to suggest that VDD may increase COVID-19 infection susceptibility, however research assessing the impact of VDD on COVID-19 symptom duration is limited. The aim of this research was to determine whether VDD is a significant independent risk factor for extended durations of COVID-19 symptoms.

Methods The study included 392 healthcare workers who isolated due to COVID-19 symptoms during the first wave of the pandemic (12th to 22nd May 2020) as part of the convalescent immunity (COCO) study. Data on 8 symptom types and duration of symptoms were collected, including patients’ demographics and co-morbidities. Anti-SARS-Cov-2 antibodies were measured using a combined IgG, IgA and IgM ELISA (The Binding Site). Vitamin D status was determined by measurement of serum 25(OH)D3 using the AB SCIEX Triple Quad 4500 mass spectrometry system. VDD was defined as serum 25(OH)D3 lt;30 nmol/L.

Results Through univariate analysis of VDD and non-VDD staff, we initially showed VDD to be significantly associated with longer durations of body aches (median 7 days, IQR 5textendash14 vs. median 5 days, IQR 3textendash7.5; p=0.0075) and fatigue (median 12 days, IQR 7textendash14 vs. median 7 days, IQR 4textendash14; p=0.0127). VDD did not influence the duration of the other 6 symptoms analysed, such as cough and fever. Using binary logistic regression models, we confirm that VDD is a significant independent risk factor for extended durations of fatigue (OR 2.089, 95.087textendash4.011; p=0.027) and body aches (OR 3.069, 95.538textendash6.124; p=0.001). Additionally, VDD staff experienced a significantly greater quantity of symptoms compared to non-VDD staff (median 5, IQR 4textendash7 versus median 4, IQR 3textendash6; p=0.0030).

Conclusions This is one of the first studies to investigate the influence of VDD on COVID-19 symptom duration. Our results indicate that VDD is a significant independent risk factor for a longer duration of body aches and fatigue. Larger studies are required to confirm these results and determine if VD supplementation could shorten symptoms.
Original languageEnglish
Pages (from-to)A170-A171
JournalThorax
Volume77
Issue numberSuppl 1
Early online date11 Nov 2022
DOIs
Publication statusPublished - 7 Jul 2023
EventBritish Thoracic Society Winter Meeting 2022 - QEII Centre, London , United Kingdom
Duration: 23 Nov 202225 Nov 2022

Fingerprint

Dive into the research topics of 'P165 Association between vitamin D deficiency and extended duration of COVID-19 symptoms'. Together they form a unique fingerprint.

Cite this